학술논문
Kinetics of serum O-glycosylated M-hepatitis B surface antigen with hepatocellular carcinoma history and nucleos(t)ide analogue therapy in hepatitis B patients.
Document Type
Academic Journal
Author
Okumura T; Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.; Joshita S; Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.; Department of Health Promotion Medicine, Shinshu University School of Medicine, Matsumoto, Japan.; Iwadare T; Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.; Wakabayashi SI; Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.; Kobayashi H; Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.; Department of Health Promotion Medicine, Shinshu University School of Medicine, Matsumoto, Japan.; Yamashita Y; Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.; Sugiura A; Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.; Kimura T; Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.; Umemura T; Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.; Department of Health Promotion Medicine, Shinshu University School of Medicine, Matsumoto, Japan.; Department of Advanced Endoscopic Therapy, Shinshu University School of Medicine, Matsumoto, Japan.; Consultation Center for Liver Diseases, Shinshu University Hospital, Matsumoto, Japan.
Source
Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 9435672 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2893 (Electronic) Linking ISSN: 13520504 NLM ISO Abbreviation: J Viral Hepat Subsets: MEDLINE
Subject
Language
English
Abstract
A newly developed O-glycosylated M-hepatitis B surface antigen (HBsAgGi) measurement system can detect hepatitis B surface antigen (HBsAg) associated with infectious particles. We investigated the association of HBsAgGi levels with clinical parameters and a history of hepatocellular carcinoma (HCC) development in a cross-sectional cohort analysis (Study 1) as well as the quantitative changes in HBsAgGi during nucleos(t)ide analogue (NA) therapy in a longitudinal cohort analysis (Study 2). A total of 124 patients with genotype C chronic HBV infection were analysed in Study 1 to evaluate correlations of HBsAgGi with conventional HBV markers and HCC history. Among those, 36 patients receiving NA therapy were enrolled in Study 2 for quantitative comparisons between pre-treatment baseline and 48 weeks of NA therapy. In Study 1, serum HBsAgGi was significantly associated with HBsAg (r = .5857, p < .00001) and weakly but significantly correlated with HBV DNA (r = .2936, p = .001). Although HBsAgGi (p = .111) was comparable between HCC history (+) group and HCC history (-) group, the HBsAgGi/HBsAg ratio (p = .011) was significantly higher in HCC history (+) patients. In Study 2, HBsAgGi was significantly decreased after 48 weeks of NA therapy (p < .001). HBsAg findings were similar (p = .005) along with an HBV DNA reduction (p < .001). In the baseline hepatitis B e antigen (HBeAg) (+) subgroup, HBsAgGi decreased significantly between baseline and 48 weeks of NA (p = .005), while HBsAg was comparable (p = .051). Low HBsAg and high HBsAgGi were associated with a history of HCC development. HBsAgGi decreased significantly by 48-week NA therapy.
(© 2023 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.)
(© 2023 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.)